论文部分内容阅读
估价乳腺癌患者的预后,观察有否肝转移甚为重要。尸检表明60%的乳腺癌患者有肝转移。临床检测肝转移的常用方法是肝扫描,但其假阳性占10～30%,而其它常用的血清指标又无高度的特异性。因此,必须寻找一种具有高度特异的诊断肝转移的标志。本文报道血清5′核苷酸磷酸二酯酶同功酶V(5′—NPD—V),作为乳腺癌肝转移的标志及其价值。作者对258例乳腺癌患者进行2年的前瞻性研究。结果表明,与异常的肝扫描相结合,此种测定可准确预示肝转移的机率为95%(39/41);若5—N′PD—V与其它肝功能试验相结合,当2种或2种以上的指标不正常或该同功酶升高2mU时,均可作为肝转移的指征。若肝扫描与5′—NPD—V同时阳性,则
To evaluate the prognosis of breast cancer patients, it is important to observe whether there is liver metastasis. Autopsy showed that 60% of breast cancer patients had liver metastases. Liver scans are commonly used for clinical detection of liver metastases, but false positives account for 10 to 30%, while other commonly used serum markers are not highly specific. Therefore, we must look for a highly specific marker for the diagnosis of liver metastases. This paper reports serum 5’ nucleotide phosphodiesterase isoenzyme V (5’-NPD-V) as a marker and value of liver metastasis in breast cancer. The authors conducted a prospective 2-year study of 258 breast cancer patients. The results showed that, combined with abnormal liver scan, this assay can accurately predict the probability of liver metastasis to be 95% (39/41); if 5-N’PD-V is combined with other liver function tests, two or more When two or more indicators are abnormal or the isoenzyme is elevated by 2mU, it can be used as an indicator of liver metastasis. If the liver scan is positive with 5′-NPD-V, then